Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Registry facet

Defined terms in the registry — page 5

195 documents of type defined term.

Documents

195 documents · page 5 of 5
  • CEI-GT-161Defined term2026-q3

    Repeated freezing and thawing of a solution. Concentrates solutes in the shrinking liquid fraction, drives pH excursion as buffer components crystallise differentially…

    30 Jul 2026
  • CEI-GT-162Defined term2026-q3

    The time a reconstituted preparation may be stored and used, supported by stability-indicating data on that presentation. The Institute publishes no in-use claim for any…

    30 Jul 2026
  • CEI-GT-163Defined term2026-q3

    Loss of peptide to container and syringe surfaces, material at low concentration in the absence of a surfactant. A source of content loss that no certificate reports.

    30 Jul 2026
  • CEI-GT-164Defined term2026-q3

    The document accompanying a batch, reporting the determinations made and the results obtained. Its value depends entirely on which fields it carries and whether the…

    30 Jul 2026
  • CEI-GT-165Defined term2026-q3

    The Institute’s specification of the fields a certificate must carry for a purity or content claim to be interpretable. Fields are classified as critical or recommended…

    30 Jul 2026
  • CEI-GT-166Defined term2026-q3

    The linkage between a certificate and the specific batch supplied, by batch identifier and date. A certificate that cannot be linked to the material in hand is a…

    30 Jul 2026
  • CEI-GT-167Defined term2026-q3

    Analysis performed by a laboratory independent of the supplier. Stronger evidence than a supplier-issued certificate, and weaker than analysis of an independently…

    30 Jul 2026
  • CEI-GT-168Defined term2026-q3

    The record of where an analysed sample came from and who selected it. A supplier-selected sample and an independently purchased one are different classes of evidence and…

    30 Jul 2026
  • CEI-GT-169Defined term2026-q3

    In an Institute supplier dossier, a determination supported by documentation the Institute has examined. Verification is of the documentation and never of the product…

    30 Jul 2026
  • CEI-GT-170Defined term2026-q3

    In an Institute supplier dossier, a claim for which the Institute has looked for supporting documentation and not found it. Distinct from not assessed.

    30 Jul 2026
  • CEI-GT-171Defined term2026-q3

    In an Institute supplier dossier, an attribute the Institute did not examine. Carries no implication about the attribute and is recorded so that a reader can distinguish…

    30 Jul 2026
  • CEI-GT-172Defined term2026-q3

    A supply designation indicating that material is not manufactured under a marketing authorisation and is not approved for human or veterinary use in any jurisdiction. A…

    30 Jul 2026
  • CEI-GT-173Defined term2026-q3

    A regulated system of controls over manufacture, in which a claim of compliance is meaningful only where an inspecting authority is named. An unverified compliance claim…

    30 Jul 2026
  • CEI-GT-174Defined term2026-q3

    The international standard for the competence of testing laboratories. Accreditation is granted for named tests within a defined scope; a laboratory accredited for one…

    30 Jul 2026
  • CEI-GT-175Defined term2026-q3

    Permission from a competent authority to place a medicine on the market for a stated indication. Specific to product, indication, presentation and jurisdiction.

    30 Jul 2026
  • CEI-GT-176Defined term2026-q3

    Holding no marketing authorisation for the use in question. A compound may be approved in one indication and unapproved in another, and approved in one jurisdiction and…

    30 Jul 2026
  • CEI-GT-177Defined term2026-q3

    Use of an authorised product outside the terms of its authorisation. A regulated product used outside its licence, and distinct from an unapproved product, though the…

    30 Jul 2026
  • CEI-GT-178Defined term2026-q3

    The most prominent warning a competent authority can require in product information. Signals regulatory concern; does not itself establish that the risk is realised in…

    30 Jul 2026
  • CEI-GT-179Defined term2026-q3

    The collection and analysis of reports of suspected adverse reactions after authorisation. Establishes that an event has been reported and, for an event named in a…

    30 Jul 2026
  • CEI-GT-180Defined term2026-q3

    Increased reporting of an adverse event following publicity about it, which inflates a pharmacovigilance signal without any change in incidence.

    30 Jul 2026
  • CEI-GT-181Defined term2026-q3

    The Anatomical Therapeutic Chemical classification assigned by the World Health Organization. Assigned to authorised substances; its absence indicates that no…

    30 Jul 2026
  • CEI-GT-182Defined term2026-q3

    A unique identifier assigned to a chemical substance by the Chemical Abstracts Service. An identifier and not a statement of legal or quality status.

    30 Jul 2026
  • CEI-GT-183Defined term2026-q3

    A preparation made by a pharmacy for an individual patient. Subject to a different regulatory framework from a manufactured medicine, and not equivalent to an authorised…

    30 Jul 2026
  • CEI-GT-184Defined term2026-q3

    The quarterly period in which the Institute ratifies documents. Every document carries the cycle in which its current version was ratified.

    30 Jul 2026
  • CEI-GT-185Defined term2026-q3

    Approval of a document by the assessment committee following external review and, where applicable, the disposition of a public comment period. A document is published…

    30 Jul 2026
  • CEI-GT-186Defined term2026-q3

    A defined window during which formal submissions may be made on a draft. Every submission is signed, carries a declared interest, receives a secretariat response and is…

    30 Jul 2026
  • CEI-GT-187Defined term2026-q3

    The Institute’s recorded decision on a submission: accepted, accepted in part, noted without amendment, or not accepted with a stated reason. Submissions that are not…

    30 Jul 2026
  • CEI-GT-188Defined term2026-q3

    A financial or non-financial relationship disclosed by a person contributing to an Institute document or submitting to a comment period. A declaration is not a…

    30 Jul 2026
  • CEI-GT-189Defined term2026-q3

    An Institute-constructed trial record representing an instalment, sub-study or regional extension of a real development programme, published to carry a methodological…

    30 Jul 2026
  • CEI-GT-190Defined term2026-q3

    A marker applied to any figure, worked example or value the Institute has constructed for teaching purposes rather than extracted from a source. The boundary between…

    30 Jul 2026
  • CEI-GT-191Defined term2026-q3

    The cycle in which a document is scheduled for re-examination. A document past its next-review date without a new version is flagged in the registry.

    30 Jul 2026
  • CEI-GT-192Defined term2026-q3

    The edition of a document. Any change to a number, a rating or a conclusion increments the version; superseded versions remain published, marked and linked from the…

    30 Jul 2026
  • CEI-GT-193Defined term2026-q3

    The record of every correction made to a published document, including corrections that do not change a conclusion. Published in full so that a reader can judge which…

    30 Jul 2026
  • CEI-GT-194Defined term2026-q3

    The record of third-party data submitted to the Institute, what was submitted, by whom, and whether it was used. Data submitted and not used are recorded with the reason.

    30 Jul 2026
  • CEI-GT-195Defined term2026-q3

    The stable reference for an Institute document, of the form CEI-XX-nnn. A document that changes type retains its original identifier so that citations to it remain…

    30 Jul 2026

page 5 of 5

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.